Physician profile
Matthias Simon
NPI 1508950130
$3,614.79
in general payments reported to CMS, 2019-2025
22 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $148 · 2021: $233 · 2022: $672 · 2023: $857 · 2024: $722 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $665.07 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $493.87 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $451.46 | 2021-2024 | |
| Opko Pharmaceuticals, LLC | $354.75 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $257.20 | 2023-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $217.91 | 2019-2025 | |
| Horizon Therapeutics Plc | $186.26 | 2019-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $168.90 | 2019-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $101.62 | 2021-2024 | Auryxia |
| Amgen INC. | $98.47 | 2023-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $80.75 | 2022-2025 | |
| Glaxosmithkline, LLC. | $76.67 | 2021-2025 | Benlysta |
| Ardelyx, INC. | $65.37 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.14 | 2024-2025 | Jardiance |
| Cormedix INC. | $52.44 | 2024 | Defencath |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $52.21 | 2022-2024 | Tarpeyo |
| Vifor Pharma, INC. | $51.04 | 2021-2024 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $46.88 | 2023 | Terlivaz |
| Ultragenyx Pharmaceutical INC. | $41.02 | 2021-2023 | Crysvita |
| Ani Pharmaceuticals, INC. | $38.07 | 2024-2025 | Purified Cortrophin Gel |
| Veloxis Pharmaceuticals, INC. | $35.87 | 2024 | Envarsus |
| Shire North American Group INC | $18.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthias Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.